Cargando…

Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain

Hyperactive mutation V617F in the JAK2 regulatory pseudokinase domain (JH2) is prevalent in patients with myeloproliferative neoplasms. Here, we identified novel small molecules that target JH2 of JAK2 V617F and characterized binding via biochemical and structural approaches. Screening of 107,600 sm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Virtanen, Anniina T., Haikarainen, Teemu, Sampathkumar, Parthasarathy, Palmroth, Maaria, Liukkonen, Sanna, Liu, Jianping, Nekhotiaeva, Natalia, Hubbard, Stevan R., Silvennoinen, Olli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865020/ https://www.ncbi.nlm.nih.gov/pubmed/36678572 http://dx.doi.org/10.3390/ph16010075

Ejemplares similares

Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling
por: Raivola, Juuli, et al.
Publicado: (2019)

Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain
por: Raivola, Juuli, et al.
Publicado: (2018)

Nucleotide-binding mechanisms in pseudokinases
por: Hammarén, Henrik M., et al.
Publicado: (2016)

Crystal structures of the Jak2 pseudokinase domain and the pathogenic mutant V617F
por: Bandaranayake, Rajintha M., et al.
Publicado: (2012)

Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
por: T. Virtanen, Anniina, et al.
Publicado: (2019)

Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response
por: Palmroth, Maaria, et al.
Publicado: (2021)

IRF2BP2 Mutation Is Associated with Increased STAT1 and STAT5 Activation in Two Family Members with Inflammatory Conditions and Lymphopenia
por: Palmroth, Maaria, et al.
Publicado: (2021)

Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response
por: Valli, Atte, et al.
Publicado: (2022)

Janus Kinases in Leukemia
por: Raivola, Juuli, et al.
Publicado: (2021)

Inhibition of RNA Binding in SND1 Increases the Levels of miR-1-3p and Sensitizes Cancer Cells to Navitoclax
por: Lehmusvaara, Saara, et al.
Publicado: (2022)

Structure of a pseudokinase domain switch that controls oncogenic activation of Jak kinases
por: Toms, Angela V., et al.
Publicado: (2013)

JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling
por: Grant, Alice H., et al.
Publicado: (2023)

Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase
por: Hubbard, Stevan R.
Publicado: (2018)

JAK Kinases in Health and Disease: An Update
por: Laurence, Arian, et al.
Publicado: (2012)

What is the point of pseudokinases?
por: Raju, Saravanan, et al.
Publicado: (2015)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

The RNA‐binding protein Snd1/Tudor‐SN regulates hypoxia‐responsive gene expression
por: Saarikettu, Juha, et al.
Publicado: (2023)

Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways
por: Zhou, Yu, et al.
Publicado: (2022)

Editorial: JAK inhibition in autoimmune and inflammatory diseases
por: Telliez, Jean-Baptiste, et al.
Publicado: (2022)

Ab Initio Modeling and Experimental Assessment of Janus Kinase 2 (JAK2) Kinase-Pseudokinase Complex Structure
por: Wan, Xiaobo, et al.
Publicado: (2013)

Pseudokinase is active after all
por: LeBrasseur, Nicole
Publicado: (2008)

Tribbles Pseudokinases in Colorectal Cancer
por: Ferreira, Bibiana I., et al.
Publicado: (2021)

Pseudokinases, Tribbles Proteins and Cancer
por: Velasco, Guillermo, et al.
Publicado: (2023)

JAK2 V617F Constitutive Activation Requires JH2 Residue F595: A Pseudokinase Domain Target for Specific Inhibitors
por: Dusa, Alexandra, et al.
Publicado: (2010)

SCYL pseudokinases in neuronal function and survival
por: Pelletier, Stephane
Publicado: (2016)

Pharmacological Targeting of the Pseudokinase Her3
por: Xie, Ting, et al.
Publicado: (2014)

Analysis of Jak2 Catalytic Function by Peptide Microarrays: The Role of the JH2 Domain and V617F Mutation
por: Sanz, Arturo, et al.
Publicado: (2011)

The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling
por: Tactacan, Carole M., et al.
Publicado: (2015)

Pseudokinases-remnants of evolution or key allosteric regulators?
por: Zeqiraj, Elton, et al.
Publicado: (2010)

The real role of pseudokinase: linking diabetes to cancers
por: Li, Ke, et al.
Publicado: (2016)

Tribbles Pseudokinase 3 Regulation and Contribution to Cancer
por: Stefanovska, Bojana, et al.
Publicado: (2021)

Phosphorylation-dependent pseudokinase domain dimerization drives full-length MLKL oligomerization
por: Meng, Yanxiang, et al.
Publicado: (2023)

Proximal ADP-ribose Hydrolysis in Trypanosomatids is Catalyzed by a Macrodomain
por: Haikarainen, Teemu, et al.
Publicado: (2016)

STRAD pseudokinases regulate axogenesis and LKB1 stability
por: Veleva-Rotse, Biliana O, et al.
Publicado: (2014)

Perturbations of the ZED1 pseudokinase activate plant immunity
por: Bastedo, D. Patrick, et al.
Publicado: (2019)

Cataloguing the dead: breathing new life into pseudokinase research
por: Shrestha, Safal, et al.
Publicado: (2020)

The Pseudokinase TRIB1 in Immune Cells and Associated Disorders
por: Danger, Richard, et al.
Publicado: (2022)

Oncogenic Signalling of PEAK2 Pseudokinase in Colon Cancer
por: Lecointre, Céline, et al.
Publicado: (2022)

Evolutionary and cellular analysis of the ‘dark’ pseudokinase PSKH2
por: Byrne, Dominic P., et al.
Publicado: (2023)

Modulators of Hepatic Lipoprotein Metabolism Identified in a Search for Small-Molecule Inducers of Tribbles Pseudokinase 1 Expression
por: Nagiec, Marek M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gjpnrcieflckulc4kgjvl0ste6